

Regimen list

Regimen	Status
- Hypersensitivity - As Required Medications - Version 3	Active
(*riTUXimab) cycloPHOSphamide, DOXOrubicin, vinCRISStine and prednisoLONE (*R)-CHOP Therapy – 14 days (00409) - Version 10	Active
(*riTUXimab) cycloPHOSphamide, DOXOrubicin, vinCRISStine and prednisoLONE (*R)-CHOP - 21 days (00307) - Version 10	Active
(*riTUXimab), Cyclophosphamide, vinCRISStine and prednisoLONE (*R)-CVP –21 days (00293) - Version 6	Active
(*riTUXimab)-Gemcitabine, cycloPHOSphamide, vinCRISStine and prednisoLONE (* R)- GCVP- 21 days (00737) - Version 5	Active
(MAP) Methotrexate (12000mg/m ²) DOXOrubicin (37.5mg/m ² /day) and CISplatin (60mg/m ²) Adj (00463.2) - Version 2	Active
(MAP) Methotrexate (12000mg/m ²) DOXOrubicin (37.5mg/m ² /day) and CISplatin (60mg/m ²) Nadj (00463.1) - Version 2	Active
5-Fluorouracil (4 day) and mitoMYcin Chemoradiation (00451) - Version 8	Active
5-Fluorouracil (5 day) and mitoMYcin Chemoradiation (00450) - Version 6	Active
5-Fluorouracil 225mg/m ² /day and Radiotherapy (RT)-Continuous infusion (7 day) (00421) - Version 7	Active
5-Fluorouracil and Folinic Acid Therapy-14 day Adj (00660.1) - Version 6	Active
5-Fluorouracil and Folinic Acid Therapy-14 day- Met (00660.2) - Version 4	Active
5-Fluorouracil, epiRUBicin 100 and cycloPHOSphamide (FEC 100) (00265) - Version 4	Active
5-Fluorouracil, epiRUBicin 50 and cycloPHOSphamide (FEC 50) (00269) - Version 4	Active
Abemaciclib Therapy (00619) - Version 3	Active
Abiraterone and prednisoLONE (mCRPC) (00103) - Version 6	Active
Abiraterone and prednisoLONE (mHSPC) (00577) - Version 4	Active
ABVD (00290) - Version 8	Active
Acalabrutinib (Capsules) Monotherapy (00656) - Version 3	Inactive
Acalabrutinib (Tablets) Monotherapy (00840) - Version 3	Active
Afatinib Monotherapy (00221) - Version 4	Active
Aflibercept and FOLFIRI -14 day (00238) - Version 3	Active
AL Amyloidosis: cycloPHOSphamide, Bortezomib and dexAMETHasone (CVD) 28 Day (00652) - Version 2	Active
Alectinib Monotherapy (00401) - Version 3	Active
Anastrozole Monotherapy Adj (00254.1) - Version 5	Active
Anastrozole Monotherapy LA/M (00254.2) - Version 4	Active
Apalutamide (00574) - Version 3	Active
Asciminib Monotherapy (00847) - Version 2	Active
Atezolizumab (SC) and Bevacizumab (IV) (00831.2) - Version 1	Active
Atezolizumab 1680mg Monotherapy – 28 Day Adj (00593.2) - Version 1	Active
Atezolizumab 1680mg Monotherapy – 28 Day Met (00593.1) - Version 4	Active
Atezolizumab 840mg Monotherapy – 14 Day Adj (00592.2) - Version 2	Active
Atezolizumab 840mg Monotherapy – 14 Day Met (00592.1) - Version 2	Active
Atezolizumab and Bevacizumab (00831.1) - Version 2	Active
Atezolizumab and nab-PACLitaxel (00688) - Version 7	Active
Atezolizumab IV Monotherapy Adj- 21 Day (00544.2) - Version 3	Active
Atezolizumab IV Monotherapy Met-21 Day (00544.1) - Version 5	Active
Atezolizumab IV, CARBOplatin (AUC 5) and Etoposide (Day 1 IV, Day 2 & 3 oral)- 21 Day (00689.3) - Version 2	Active
Atezolizumab IV, CARBOplatin (AUC 5) and Etoposide 100mg/m ² - 21 Day (00689.1) - Version 5	Active
Atezolizumab SC Monotherapy Adj- 21 Day (00544.4) - Version 2	Active
Atezolizumab SC Monotherapy Met- 21 Day (00544.3) - Version 2	Active
Atezolizumab SC, CARBOplatin (AUC 5) and Etoposide (Day 1 IV, Day 2 & 3 oral)- 21 Day (00689.4) - Version 2	Active
Atezolizumab SC, CARBOplatin (AUC 5) and Etoposide 100mg/m ² - 21 Day (00689.2) - Version 2	Active
Avelumab Monotherapy (00535) - Version 6	Active
Axitinib Monotherapy (00104) - Version 3	Active
azaCITIDine (Oral) Monotherapy (00818) - Version 2	Active
azaCITIDine 100mg/m ² IV 5-day (00288.2) - Version 3	Active
azaCITIDine 100mg/m ² SC 5-day (00288.1) - Version 9	Active
azaCITIDine 75mg/m ² IV 5-2-2 (00287.2) - Version 3	Active

Regimen list

Regimen	Status
azaCITIDine 75mg/m ² SC 5-2-2 (00287.1) - Version 9	Active
BEAM Autologous Transplant Conditioning Protocol (00408) - Version 3	Active
Bendamustine Monotherapy (00527) - Version 4	Active
Bevacizumab 10mg/kg - 14 days (00212) - Version 5	Active
Bevacizumab 10mg/kg and PACLitaxel 80mg/m ² (00738) - Version 5	Active
Bevacizumab 10mg/kg and PACLitaxel 80mg/m ² (Day 1, 8, 15 and 22) (00769) - Version 3	Active
Bevacizumab 10mg/kg and Pegylated liposomal DOXOrubicin 40mg/m ² (00772) - Version 3	Active
Bevacizumab 10mg/kg and Topotecan 4mg/m ² (00771) - Version 3	Active
Bevacizumab 15mg/kg - 21 days (00215) - Version 6	Active
Bevacizumab 15mg/kg, CARBOplatin (AUC 6) and PACLitaxel 175mg/m ² (00766) - Version 2	Active
Bevacizumab 15mg/kg, CARBOplatin (AUC5) and PACLitaxel 175mg/m ² (00716) - Version 2	Active
Bevacizumab 15mg/kg, PACLitaxel 175mg/m ² and CISplatin 50mg/m ² (00799) - Version 2	Active
Bevacizumab 5mg/kg -14 days - Version 2	Inactive
Bevacizumab 5mg/kg and FOLFIRI – 14 days (00449) - Version 7	Active
Bevacizumab 5mg/kg and FOLFOXIRI - 14 days (00783) - Version 3	Active
Bevacizumab 5mg/kg and Modified FOLFOX- 6 – 14 days (00446) - Version 8	Active
Bevacizumab 5mg/kg Monotherapy – 14 Day (00813) - Version 2	Active
Bevacizumab 5mg/kg, 5-Fluorouracil and Folinic Acid Therapy-14 day (00791) - Version 2	Active
Bevacizumab 7.5mg/kg – 21 days (00214) - Version 5	Active
Bevacizumab 7.5mg/kg and Capecitabine 1250mg/m ² Therapy- 21 day (00623) - Version 5	Active
Bevacizumab 7.5mg/kg, CARBOplatin(AUC5) and PACLitaxel 175mg/m ² (00620) - Version 5	Active
Bicalutamide (00482) - Version 4	Active
Bleomycin, Etoposide and CISplatin (BEP) (00300) - Version 5	Active
Blinatumomab (00538) - Version 2	Active
Blinatumomab (ALL with MRD ≥ 0.1%) (00590) - Version 2	Active
Bortezomib (Weekly), Melphalan & Prednisolone (00275.2) - Version 1	Active
Bortezomib and dexAMETHasone (00270) - Version 6	Active
Bortezomib and Lenalidomide (RVD-Lite) Consolidation (00781) - Version 5	Active
Bortezomib Maintenance - 14 day (00435) - Version 5	Active
Bortezomib, dexAMETHasone, Thalidomide, CISplatin, DOXOrubicin, cycloPHOSphamide and Etoposide (VDT PACE) (00496) - Version 1	Active
Bortezomib, Lenalidomide and dexAMETHasone (RVD) - 21 day (00416) - Version 6	Active
Bortezomib, Lenalidomide and dexAMETHasone (RVD) Therapy - 28 day (00643) - Version 5	Active
Bortezomib, Lenalidomide and dexAMETHasone (RVD-Lite) Induction (00780) - Version 5	Active
Bortezomib, Melphalan & Prednisolone (00275.1) - Version 4	Active
Bortezomib, Thalidomide and Dexamethasone (VTD) Induction (00274) - Version 5	Active
Bosutinib Monotherapy (00224) - Version 3	Active
Brentuximab vedotin and Bendamustine (00529) - Version 4	Active
Brentuximab vedotin and cycloPHOSphamide, DOXOrubicin and prednisoLONE (CHP) (00801) - Version 3	Active
Brentuximab vedotin and ESHAP (BRESHAP) (00530) - Version 3	Active
Brentuximab vedotin and ICE (00528) - Version 5	Active
Brentuximab vedotin Monotherapy (00234) - Version 4	Active
Brigatinib (00562) - Version 4	Active
Busulfan,cycloPHOSphamide – MAC – SIB (00641) - Version 5	Active
Busulfan,cycloPHOSphamide,ATG Grafalon® – MAC – Mismatched Sibling Donor (00662) - Version 5	Active
Busulfan,cycloPHOSphamide,ATG Grafalon® – MAC – Mismatched Unrelated Donor (00663) - Version 5	Active
Busulfan,cycloPHOSphamide–MAC–MUD (00639) - Version 4	Active

Regimen list

Regimen	Status
Cabazitaxel 20mg/m ² and prednisoLONE (00101.2) - Version 1	Active
Cabazitaxel 25mg/m ² and prednisoLONE (00101.1) - Version 4	Active
Cabozantinib Therapy (00518) - Version 4	Active
Capecitabine 825mg/m ² and Radiotherapy-7 day (00586) - Version 4	Active
Capecitabine 830mg/m ² and Radiotherapy – 7 day (00523) - Version 7	Active
Capecitabine and Oxaliplatin Therapy (XELOX) Adj (00321.1) - Version 9	Active
Capecitabine and Oxaliplatin Therapy (XELOX) Met (00321.2) - Version 8	Active
Capecitabine and Temozolomide (00505) - Version 4	Active
Capecitabine Monotherapy Adj (00216.1) - Version 7	Active
Capecitabine Monotherapy LA/M (00216.2) - Version 7	Active
CARBOplatin (AUC 2) Weekly and PACLitaxel (50mg/m ²) Weekly with Radiotherapy (RT) -5 weeks (00422) - Version 9	Active
CARBOplatin (AUC 2) weekly and PACLitaxel 80mg/m ² followed by Dose Dense DOXOrubicin cycloPHOSphamide - Triple Negative Breast Cancer (00734) - Version 3	Active
CARBOplatin (AUC 2) Weekly with Radiotherapy (RT) (00419) - Version 8	Active
CARBOplatin (AUC 3), Etoposide (50mg/m ²) and Thoracic Radiotherapy (TRT) -28 day (00561) - Version 3	Active
CARBOplatin (AUC 5) + Etoposide (Day 1 IV, Day 2 & 3 oral) -21 day (00271.2) - Version 1	Active
CARBOplatin (AUC 5) and 5-Fluorouracil 1000mg/m ² /day – 28 day (00552) - Version 10	Active
CARBOplatin (AUC 6) and PACLitaxel 200mg/m ² (00304) - Version 8	Active
CARBOplatin (AUC1.5) Chemoradiation - 7 days (00332) - Version 7	Active
CARBOplatin (AUC5) and Etoposide 100mg/m ² - 21 days (00271.1) - Version 14	Active
CARBOplatin (AUC6) and Weekly PACLitaxel 80mg/m ² (00308.2) - Version 5	Active
CARBOplatin (AUC6) and Weekly PACLitaxel 80mg/m ² Adj (00308.1) - Version 4	Active
CARBOplatin (AUC6) and Weekly PACLitaxel 80mg/m ² followed by Dose Dense DOXOrubicin cycloPHOSphamide - Triple Negative Breast Cancer (00348) - Version 7	Active
CARBOplatin (AUC7) and Etoposide- Autologous Conditioning Germ Cell Tumour (00453) - Version 3	Active
CARBOplatin 70mg/m ² and 5-Fluorouracil 600mg/m ² with Radiotherapy (00589) - Version 4	Active
CARBOplatin and Oral Etoposide - 21days (00319) - Version 7	Active
CARBOplatin and vinorelbine (Oral vinorelbine) -21 Day (00614.2) - Version 1	Active
CARBOplatin and vinorelbine Therapy-21 Day (00614.1) - Version 5	Active
CARBOplatin AUC 4 and 5-Fluorouracil 600mg/m ² with Radiotherapy (00591) - Version 7	Active
CARBOplatin AUC 5 and Pegylated Liposomal DOXOrubicin 30mg/m ² -28 day (00624) - Version 3	Active
CARBOplatin AUC4 Monotherapy-21 days (00261.3) - Version 7	Active
CARBOplatin AUC4 Monotherapy-28 days (00251.3) - Version 6	Active
CARBOplatin AUC5 and PACLitaxel 175mg/m ² Adj (00303.7) - Version 8	Active
CARBOplatin AUC5 and PACLitaxel 175mg/m ² Met (00303.8) - Version 7	Active
CARBOplatin AUC5 Monotherapy-21 days (00261.2) - Version 7	Active
CARBOplatin AUC5 Monotherapy-28 days (00251.2) - Version 6	Active
CARBOplatin AUC6 and PACLitaxel 175mg/m ² Adj (00303.5) - Version 7	Active
CARBOplatin AUC6 and PACLitaxel 175mg/m ² Met (00303.6) - Version 8	Active
CARBOplatin AUC6 Monotherapy-21 days (00261.1) - Version 9	Active
CARBOplatin AUC6 Monotherapy-28 days (00251.1) - Version 8	Active
CARBOplatin AUC7 and PACLitaxel 175mg/m ² Adj (00303.3) - Version 7	Active
CARBOplatin AUC7 and PACLitaxel 175mg/m ² Met (00303.4) - Version 7	Active
CARBOplatin AUC7.5 and PACLitaxel 175mg/m ² Adj (00303.1) - Version 9	Active
CARBOplatin AUC7.5 and PACLitaxel 175mg/m ² Met (00303.2) - Version 10	Active
Carfilzomib (20/70mg/m ² Once weekly) dexAMETHasone (Kd) - 28 day (00595) - Version 4	Active
Carfilzomib (27mg/m ² twice weekly), Lenalidomide and dexAMETHasone (KRd) - 28 day (00405) - Version 6	Active

Regimen list

Regimen	Status
Carfilzomib (56mg/m ² once weekly) Lenalidomide and dexAMETHasone (KRd) Therapy - 28 day (00598) - Version 4	Active
Carfilzomib and dexAMETHasone (Kd) - 28 day (00566) - Version 7	Active
Carmustine,Etoposide,Cytarabine,Melphalan,Alemtuzumab RIC-SIB/MUD (00638) - Version 4	Active
Cemiplimab (00812) - Version 4	Active
Ceritinib Monotherapy (00340) - Version 2	Active
Cetuximab – 14 days (00732) - Version 3	Active
Cetuximab - 7 day (12 weeks) (00207.1) - Version 7	Active
Cetuximab - 7 day (8 weeks) (00207.2) - Version 7	Active
Cetuximab (14 days) and FOLFIRI (14 days) (00585) - Version 5	Active
Cetuximab (14 days) and Irinotecan (14 days) (00331) - Version 5	Active
Cetuximab (7 days) and FOLFIRI (14 days) (00328) - Version 8	Active
Cetuximab (7 days) and Irinotecan (14 days) (00330) - Version 5	Active
Cetuximab (weekly), CARBOplatin AUC 5 and 5-Fluorouracil 1000mg/m ² /day - 21 day (00418) - Version 11	Active
Cetuximab (weekly), CISplatin 100mg/m ² and 5-Fluorouracil 1000mg/m ² /day - 21 day cycle (00417) - Version 8	Active
Cetuximab and FOLFOX-4 (00692) - Version 3	Active
Cetuximab and FOLFOX-6 (modified) (00733) - Version 4	Active
CHI AML MyeChild Course 1 - mitoXANTRONE, Cytarabine and ONE dose gemtuzumab ozogamicin (for patients ≥1 year and >10kg and BSA ≥ 0.5m ²) - Version 2	Inactive
CHI AML MyeChild Course 1 - mitoXANTRONE, Cytarabine and THREE dose gemtuzumab ozogamicin (for patients ≥1 year and >10kg and BSA ≥0.5m ²) - Version 3	Inactive
CHI AML MyeChild Course 1 - mitoXANTRONE, Cytarabine and TWO dose Gemtuzumab Ozogamicin (<1 year or ≤10kg or BSA <0.5m ²) - Version 2	Inactive
CHI AML MyeChild Course 2 - FLA IDA (for HR patients <1 year or ≤10kg or BSA <0.5m ²) - Version 2	Inactive
CHI AML MyeChild Course 2 – FLA IDA (for HR patients ≥1 year and >10kg and BSA ≥0.5m ²) - Version 2	Inactive
CHI AML MyeChild Course 2 - mitoXANTRONE, Cytarabine (for non HR patients <1 year or ≤10kg or BSA <0.5m ²) - Version 2	Inactive
CHI AML MyeChild Course 2 - mitoXANTRONE, Cytarabine (for non HR patients ≥1 year and >10kg and BSA ≥0.5m ²) - Version 2	Inactive
CHI AML MyeChild Course 3 - FLA (for HR patients ≥1 year and >10kg and BSA ≥0.5m ²) - Version 1	Inactive
CHI AML MyeChild Course 3 - FLA (for HR patients <1 year or ≤10kg or BSA <0.5m ²) - Version 1	Inactive
CHI AML MyeChild Course 3 - FLA IDA (for IR and HR patients <1 year or ≤10kg or BSA <0.5m ²) - Version 1	Inactive
CHI AML MyeChild Course 3 - FLA IDA (for IR and HR patients ≥1 year and >10kg and BSA ≥0.5m ²) - Version 1	Inactive
CHI AML MyeChild Course 3 and 4 - FLA (for SR patient ≥1 year and >10kg and BSA ≥0.5m ²) - Version 1	Inactive
CHI AML MyeChild Course 3 and 4 - FLA (for SR patients <1 year or ≤10kg or BSA <0.5m ²) - Version 2	Inactive
CHI AML MyeChild Course 3 and 4 - HD Cytarabine (for SR patients <1 year or ≤10kg or BSA <0.5m ²) - Version 2	Inactive
CHI AML MyeChild Course 3 and 4 - HD Cytarabine (for SR patients ≥1 year and >10kg and BSA ≥0.5m ²) - Version 1	Inactive
CHI AML MyeChild Course 4 - High Dose Cytarabine (for IR patients <1 year or ≤10kg or BSA <0.5m ²) - Version 1	Inactive
CHI AML MyeChild Course 4 - High Dose Cytarabine (for IR patients ≥1 year and >10kg and BSA ≥0.5m ²) - Version 1	Inactive
CHI ES IE/VC Consolidation Euro Ewing 2012 - Version 1	Active
CHI ES VDC/IE Induction Euro Ewing 2012 - Version 3	Active
CHI HBL PHITT Group B (CISplatin with STS Anhydrous) for patients ≥ 10kg - Version 1	Active
CHI HBL PHITT Group C C5VD with STS Anhydrous for patients ≥10kg - Version 1	Active
CHI HBL PHITT Group C CDDP-M (CISplatin with STS Anhydrous) for patients ≥10kg - Version 1	Active

Regimen list

Regimen	Status
CHI HBL PHITT Group C SIOPEL-3HR with Sodium Thiosulphate Anhydrous for patients $\geq 10\text{kg}$ - Version 1	Active
CHI HBL PHITT Group D Induction for patients $\geq 10\text{kg}$ - Version 3	Active
CHI HBL PHITT Group D1 Consolidation CARBOplatin and DOXOrubicin (CD) for patients $\geq 10\text{kg}$ - Version 1	Inactive
CHI HBL PHITT Group D2 Consolidation CD/CE for patients $\geq 10\text{kg}$ - Version 1	Inactive
CHI HBL PHITT Group D2 Consolidation CD/VI for patients $\geq 10\text{kg}$ - Version 1	Inactive
CHI HL COPDAC Consolidation (2 cycles) - Version 3	Active
CHI HL COPDAC Consolidation (4 cycles) - Version 3	Active
CHI HL DECOPDAC Consolidation (2 cycles) - Version 2	Active
CHI HL DECOPDAC Consolidation (4 cycles) - Version 2	Active
CHI HL OEPA Induction CHI1069 - Version 2	Active
CHI LCH IV Continuation Arm A for patients $\geq 10\text{kg}$ - Version 1	Active
CHI LCH IV Continuation Arm B for patients $\geq 10\text{kg}$ - Version 1	Active
CHI LCH IV Continuation Arm C for patients $\geq 10\text{kg}$ - Version 1	Active
CHI LCH IV Continuation Arm D for patients $\geq 10\text{kg}$ - Version 1	Active
CHI LCH IV Stratum 1 Initial course 1 (weekly vinBLASTine) for patients $\geq 10\text{kg}$ (CHI 1106.1) - Version 1	Active
CHI LCH IV Stratum 1 Initial course 2 (weekly vinBLASTine) for patients $\geq 10\text{kg}$ (CHI 1107.1) - Version 1	Active
CHI LGG Standard Consolidation (patients aged ≥ 1 year) CHI1061.1 - Version 2	Active
CHI LGG Standard Consolidation (patients aged 6months – 1 year) CHI1061.2 - Version 3	Inactive
CHI LGG Standard Consolidation (patients aged less than 6months) CHI1061.3 - Version 3	Inactive
CHI LGG Standard Induction (patients aged ≥ 1 year) CHI1060.1 - Version 2	Active
CHI LGG Standard Induction (patients aged 6months – 1 year) CHI1060.2 - Version 3	Active
CHI LGG Standard Induction (patients aged less than 6months) - Version 3	Active
CHI LGG weekly vinBLASTine (BSA $<0.6\text{m}^2$) CHI1062.2 - Version 4	Active
CHI LGG weekly vinBLASTine (BSA $\geq 0.6\text{m}^2$) CHI1062.1 - Version 4	Active
CHI RMS IVA (9 cycles) for patients > 1 year and $> 10\text{kg}$ - Version 1	Inactive
CHI RMS VA (8 cycles) for patients > 1 year and $> 10\text{kg}$ - Version 1	Inactive
CHI UKALL 2019 Regimen A Maintenance with IT Methotrexate (CHI1144.1) - Version 1	Active
CHI UKALL 2019 Regimen B Maintenance with IT Methotrexate (CHI1145.1) - Version 1	Active
CHI UKALL 2019 Regimen C Maintenance with IT Methotrexate (CHI1146.1) - Version 1	Active
CHI WT Post Op HR-1 (loc) for patients $\geq 12\text{kg}$ (CCLG Clinical Management Guidelines) CHI1081.1 - Version 1	Inactive
CHI WT Post Op HRm for patients $\geq 12\text{kg}$ (CCLG Clinical Management Guidelines). - Version 1	Inactive
ChIVPP (Chlorambucil, vinBLASTine, Procarbazine, prednisoLONE) (00452) - Version 1	Active
Chlorambucil $10\text{mg}/\text{m}^2$ (00411) - Version 3	Active
CHOEP – 21 days (00396.1) - Version 5	Active
CHOEP (Etoposide Day 1 IV, Days 2 & 3 PO) – 21 days (00396.2) - Version 2	Active
Cidofovir - Version 1	Active
CISplatin ($100\text{mg}/\text{m}^2$) with Radiotherapy (RT) - 21 day (00387) - Version 8	Active
CISplatin ($40\text{mg}/\text{m}^2$) Weekly with Radiotherapy (RT) (5 cycles) (00385.1) - Version 10	Active
CISplatin ($40\text{mg}/\text{m}^2$) Weekly with Radiotherapy (RT) (6 cycles) (00385.2) - Version 9	Active
CISplatin ($50\text{mg}/\text{m}^2$) and Etoposide ($50\text{mg}/\text{m}^2$) and Thoracic Radiotherapy (TRT) -28 day (00456) - Version 7	Active
CISplatin ($50\text{mg}/\text{m}^2$) Chemoradiation followed by CARBOplatin (AUC 5) and PACLitaxel ($175\text{mg}/\text{m}^2$) – Endometrial Cancer (00676) - Version 6	Active
CISplatin ($75\text{mg}/\text{m}^2$) + Etoposide - 21 day (00280.2) - Version 8	Active

Regimen list

Regimen	Status
CISplatin (75mg/m ²) + Etoposide (100mg/m ²) + Radiotherapy (RT) -21 day (00279.1) - Version 8	Active
CISplatin (75mg/m ²) + Etoposide (Day 1 IV, Day 2 & 3 Oral) + Radiotherapy (RT) -21 day (00279.2) - Version 2	Active
CISplatin (75mg/m ²) + Etoposide (Day 1 IV, Day 2 & 3 Oral) -21 day (00280.1) - Version 2	Active
CISplatin 75mg/m ² and 5-Fluorouracil Chemoradiation - Herskovic Regimen (00460) - Version 8	Active
CISplatin and 5-Fluorouracil- 28 day cycle (00314) - Version 5	Active
CISplatin and Capecitabine Adjuvant Chemoradiation (00473) - Version 3	Active
CISplatin, 5-Fluorouracil and Radiation Therapy (00594) - Version 5	Active
CISplatin, Lomustine and vinCRISTine (CLV) (00806) - Version 3	Active
CISplatin, Methotrexate and vinBLASTine (CMV) (00337) - Version 3	Active
Cladribine 0.14mg/kg Day 1 to 5 Therapy (00402) - Version 4	Active
Cladribine 0.14mg/kg Weekly (00469) - Version 5	Active
Cladribine 5 day and riTUXimab (00531) - Version 3	Active
Cladribine Weekly and riTUXimab (00534) - Version 3	Active
Cobimetinib and Vemurafenib (00373) - Version 2	Active
COMP- Amivantamab (PAPILLON) ≥80kg - Version 1	Active
COMP- Amivantamab (PAPILLON)<80Kg - Version 1	Active
COMP- Amivantamab <80kg - Version 2	Active
COMP- Amivantamab ≥ 80kg - Version 1	Active
COMP- Belantamab mafadotin (IV) - Version 1	Active
COMP- Dostarlimab (IV) - Version 1	Active
COMP- Dostarlimab with CARBOplatin and PACLitaxel - Version 1	Active
COMP- Durvalumab in combination with COMP Tremelimumab - Version 2	Active
COMP- Durvalumab Monotherapy 1500 mg – 28 Day - Version 1	Active
COMP- Elranatamab subcutaneous (SC) - Version 2	Active
COMP- Encorafenib and Cetuximab - Version 1	Active
COMP- Enhertu Breast Cancer - Version 2	Active
COMP- Epcoritamab subcutaneous (SC) - Version 1	Active
COMP- Glofitamab for intravenous infusion Compassionate Use Programme (CUP) - Version 2	Active
COMP- Lenvatinib in combination with COMP Pembrolizumab 200mg - Version 1	Active
COMP- Linvoseltamab (IV) - Version 3	Active
COMP- Mosunetuzumab for intravenous infusion Compassionate Use Programme (CUP) - Version 1	Active
COMP- Pembrolizumab (Keytruda) - Version 1	Active
COMP- Pembrolizumab in combination with chemotherapy (Nadj) and Pembrolizumab monotherapy (Adj) locally advanced or early stage TNBC high risk of recurrence - Version 1	Active
COMP- Pembrolizumab, DOCEtaxel, CARBOplatin (AUC 6) - Version 1	Active
COMP- Pertuzumab and Trastuzumab for HER2 positive Colon Cancer - Version 1	Active
COMP- Pralsetinib (PO) - Version 1	Active
COMP- Sacituzumab govitecan (IV) - Version 2	Active
COMP- Talquetamab Subcutaneous (SC) (Every two weeks) - Version 2	Active
COMP- Tebentafusp (IV) GUH - Version 1	Active
COMP- Teclistamab subcutaneous (SC) - Version 2	Active
COMP- Tepotinib (PO) - Version 1	Active
COMP- Tucatinib with Capecitabine and Trastuzumab SC - Version 1	Active
Crizotinib Monotherapy (00243) - Version 6	Active
CT- ABBIL1TY NSCLC-06 (ARM A - Pembrolizumab and Acasunlimab (GEN1046) - Version 1	Active
CT- ABBIL1TY NSCLC-06 (ARM B - Docetaxel) - Version 1	Active
CT- ARGX-113-2402 (Double-Blinded Treatment Period (DBTP) - ARGX-113/ Placebo) - Version 1	Active
CT- ARGX-113-2402 (Open-label Treatment Period (OLTP 1) - Efgartigimod (ARGX-113) - Version 1	Active
CT- ARGX-113-2402 (Open-label Treatment Period (OLTP 2) - Efgartigimod (ARGX-113) - Version 1	Active

Regimen list

Regimen	Status
CT- ASCENT-05 (ARM A - Sacituzumab govitecan and Pembrolizumab) - Version 1	Active
CT- ASCENT-05 (ARM B - Pembrolizumab) - Version 1	Active
CT- ASTER ANT-007 (Abelacimab) - Version 1	Active
CT- CA057-001 (ARM A1- Mezigdomide 1mg, Bortezomib, dexAMETHasone 20mg) - Version 1	Active
CT- CA057-001 (ARM A2- Mezigdomide 0.6mg, Bortezomib, dexAMETHasone 20mg) - Version 1	Active
CT- CA057-001 (ARM A3- Mezigdomide 0.3mg, Bortezomib, dexAMETHasone 20mg) - Version 1	Active
CT- CA057-001 (ARM B- (PVD) Pomalidomide, Bortezomib, dexAMETHasone 20mg) - Version 1	Active
CT- CC-220-MM-002 (ARM A- Iberdomide (CC-220) 1mg, Daratumumab (SC) 1800mg, dexAMETHasone 40mg) - Version 2	Active
CT- CC-220-MM-002 (ARM B- (DVd) Daratumumab (SC) 1800mg, Bortezomib ,dexAMETHasone 20mg) - Version 2	Active
CT- CHRONOS-3 Copanlisib (BAY 80-6946) - Version 1	Active
CT- CLL-18 (MOIRAI) (Arm A - Venetoclax (paper Rx) and Obinutuzumab) - Version 2	Active
CT- CompARE (ARM 1- Weekly cisplatin 40mg/m ² IV with Intensity Modulated Radiotherapy) - Version 1	Active
CT- CompARE (ARM 5- Durvalumab) (Adj) - Version 1	Active
CT- CPD-DARA CTRIAL-IE 19-17 - Version 3	Active
CT- DeLLphi-305 (20200041) (Control ARM - Durvalumab Monotherapy) - Version 1	Active
CT- DeLLphi-305 (20200041) (Investigational ARM - Tarlatamab and Durvalumab) - Version 1	Active
CT- DeLLphi-305 (20200041) (Pre-screening) - CARBOplatin, Etoposide and Durvalumab - Version 1	Active
CT- DESTINY-Breast 15 (DS8201-0001-CIS-MA) Trastuzumab deruxtecan - Version 1	Active
CT- DREAMM-10 (ARM A- Belantamab mafodotin (Lenalidomide and Dexamethasone Paper Rx) - Version 1	Active
CT- DREAMM-10 (ARM B- Daratumumab 1800mg SC (Lenalidomide and Dexamethasone Paper Rx) - Version 1	Active
CT- ETOP 25-23 ADOPT-lung (Adjuvant- Durvalumab) - Version 1	Active
CT- ETOP 25-23 ADOPT-lung (Neoadjuvant all histologies - Durvalumab, PACLitaxel and CARBOplatin) - Version 1	Active
CT- ETOP 25-23 ADOPT-lung (Neoadjuvant nonsquamous- Durvalumab, CISplatin and PEMEtrexed) - Version 1	Active
CT- ETOP 25-23 ADOPT-lung (Neoadjuvant nonsquamous- Durvalumab, PEMEtrexed and CARBOplatin) - Version 1	Active
CT- GLORIOSA (IMGN853-0421) (ARM 1- Mirvetuximab soravtansine (IMGN853) and Bevacizumab) - Version 3	Active
CT- GLORIOSA (IMGN853-0421) (ARM 2- Bevacizumab) - Version 1	Active
CT- INCA 34176-355 (Axatilimab 0.3mg/kg) - Version 1	Active
CT- INCA 34176-357 (ARM 1- Axatilimab/Placebo 0.3mg/kg Cycles 1-6) - Version 1	Active
CT- INCA 34176-357 (ARM 1- Axatilimab/Placebo 0.3mg/kg from Cycle 7 onwards every 2 weeks) - Version 1	Active
CT- INCA 34176-357 (ARM 1- Axatilimab/Placebo 0.6mg/kg from Cycle 7 onwards every 4 weeks) - Version 1	Active
CT- INCMOR 0208-305 Tafasitamab and Lenalidomide - Version 1	Active
CT- Independence (ACE-536-MF-002) (Open Label Treatment Period- Luspatercept) - Version 1	Active
CT- Isa-RVD (CTRIAL-IE 19-34) (Maintenance phase High risk + transplant) Isatuximab, Bortezomib - Version 1	Active
CT- Krystal-4 (CA2390004) (Maintenance ARM - Pembrolizumab and PEMEtrexed) - Version 1	Active
CT- Krystal-4 (CA2390004) (Treatment ARM - Pembrolizumab, PEMEtrexed and CARBOplatin (Cycles 1-4) - Version 1	Active
CT- Krystal-7 (849-007) (Comparator Arm - Pembrolizumab single agent) - Version 1	Active
CT- Krystal-7 (849-007) (Comparator ARM (Cohort 4) Pembrolizumab) - Version 1	Active

Regimen list

Regimen	Status
CT- Krystal-7 (849-007) (Investigational Arm - Adagrasib (paper Rx) and Pembrolizumab) - Version 1	Active
CT- Krystal-7 (849-007) (Investigational ARM (Cohort 3) Adagrasib and Pembrolizumab) - Version 1	Active
CT- MAGNOLIA ANT-008 (Abelacimab) - Version 1	Active
CT- MajesTEC-4 (ARM A- Teclistamab and Lenalidomide) - Version 1	Active
CT- MajesTEC-4 (ARM B- Lenalidomide alone) - Version 1	Active
CT- MajesTEC-4 (ARM C- Teclistamab alone) - Version 1	Active
CT- NeoCOAST-2 (ARM 1- Oleclumab and Durvalumab) - Version 4	Active
CT- NeoCOAST-2 (ARM 2- Monalizumab and Durvalumab) - Version 4	Active
CT- NeoCOAST-2 (ARM 6 (Adeno) - Rilvegostomig, PEMEtrexed and CARBOplatin) - Version 2	Active
CT- NeoCOAST-2 (ARM 6 (Adeno) - Rilvegostomig, PEMEtrexed and CISplatin) - Version 1	Active
CT- NeoCOAST-2 (ARM 6 (SCC) - Rilvegostomig, PACLitaxel and CARBOplatin) - Version 2	Active
CT- NeoCOAST-2 (Arm 7 - Datopotamab deruxtecan, Rilvegostomig and CARBOplatin) - Version 2	Active
CT- NeoCOAST-2 (Maintenance - Rilvegostomig) - Version 2	Active
CT- NeoCOAST-2 CARBOplatin AUC5 and PACLitaxel 175mg/m ² (NAdj) - Version 2	Active
CT- NeoCOAST-2 PEMEtrexed 500mg/m ² and CISplatin 75mg/m ² (NAdj) - Version 1	Active
CT- NRG-HN009 (ARM 1/3 - CISplatin (100mg/m ²) intravenously (IV) every 3 weeks (on day 1,22 and 43) during radiation) - Version 2	Active
CT- NRG-HN009 (ARM 2/4- CISplatin 40 mg/m ² /day IV weekly for 7 weeks during radiation) - Version 2	Active
CT- R2810-ONC-1788 (Part 1 (Blinded) Cemiplimab/Placebo) - Version 2	Active
CT- R2810-ONC-1788 (Part 2 (unblinded) Cemiplimab) - Version 2	Active
CT- R3767-ONC-2011 Fianlimab + Cemiplimab versus Pembrolizumab versus Cemiplimab - Version 1	Active
CT- R3767-ONC-2055 Fianlimab and Cemiplimab OR Pembrolizumab - Version 1	Active
CT- RAMP301 (Investigator Choice - PACLitaxel) - Version 1	Active
CT- RAMP301 (Investigator Choice - Pegylated liposomal DOXOrubicin) - Version 1	Active
CT- RECHARGE (CA071-1000) (PART ONE - DOCEtaxel) - Version 1	Active
CT- RECHARGE (CA071-1000) (PART TWO - DOCEtaxel) - Version 1	Active
CT- RENEW (KER-050-D301) (Extension phase - Elritercept/placebo) - Version 1	Active
CT- RENEW (KER-050-D301) (Primary phase - Elritercept/placebo) - Version 1	Active
CT- RENEW (KER-050-D301) (Secondary phase - Elritercept/placebo) - Version 1	Active
CT- SMT112-3003 (HARMONi-3) (Arm A + B Ivonescimab/ Pembrolizumab/Placebo) Plus PACLitaxel and CARBOplatin - Version 2	Active
CT- SMT112-3003 (HARMONi-3) (Non-squamous ARM - Ivonescimab/Pembrolizumab/Placebo) Plus PEMEtrexed and CARBOplatin) - Version 2	Active
CT- SMT112-3003 (HARMONi-3) (Non-squamous Lung - Ivonescimab or Pembrolizumab) Plus Pemetrexed and CARBOplatin) - Version 2	Active
CT- SMT112-3003 (HARMONi-3) (Squamous Lung - Ivonescimab or Pembrolizumab) Plus PACLitaxel and CARBOplatin) - Version 1	Active
CT- Tacti-004 (Non squamous - CARBOplatin, PEMEtrexed, Pembrolizumab and Eftilagimod alfa/placebo) - Version 2	Active
CT- Tacti-004 (Squamous - CARBOplatin, PACLitaxel, Pembrolizumab and Eftilagimod alfa/placebo) - Version 2	Active
CT- TroFuse-020 (ARM 1- Sacituzumab tirumotecan (MK-2870)) - Version 1	Active
CT- TroFuse-020 (ARM 2- Gemcitabine) - Version 2	Active
CT- TroFuse-020 (ARM 2- Irinotecan 100mg/m ²) - Version 2	Active
CT- TroFuse-020 (ARM 2- Irinotecan 125mg/m ²) - Version 2	Active
CT- TroFuse-020 (ARM 2- PEMEtrexed) - Version 1	Active
CT- TroFuse-020 (ARM 2- Vinorelbine) - Version 2	Active

Regimen list

Regimen	Status
CT- TroFuse-023 (MK2870-023)- Induction Therapy (Pembrolizumab, nab-PACLitaxel and CARBOplatin) - Version 1	Active
CT- TroFuse-023 (MK2870-023)- Induction Therapy (Pembrolizumab, PACLitaxel and CARBOplatin) - Version 1	Active
CT-NeoCOAST-2 PEMetrexed 500mg/m ² and CARBOplatin AUC5 (NAdj) - Version 1	Active
cycloPHOSphamide (IV) Methotrexate and 5-Fluorouracil (CMF) 21 Day Adj (00381.1) - Version 8	Active
cycloPHOSphamide (IV) Methotrexate and 5-Fluorouracil (CMF) 21 Day Met (00381.2) - Version 6	Active
cycloPHOSphamide (IV) Methotrexate and 5-Fluorouracil (CMF) 28 day Adj (00378.1) - Version 5	Active
cycloPHOSphamide (IV) Methotrexate and 5-Fluorouracil (CMF) 28 Day Met (00378.2) - Version 5	Active
cycloPHOSphamide (Oral) Methotrexate and 5-Fluorouracil (CMF) Met (00377.2) - Version 4	Active
cycloPHOSphamide 1500mg/m ² For Stem Cell Mobilisation (00795) - Version 2	Active
cycloPHOSphamide 2000mg/m ² for Stem Cell mobilisation (00438) - Version 3	Active
cycloPHOSphamide(Oral) Methotrexate and 5-Fluorouracil (CMF) Adj (00377.1) - Version 4	Active
Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) 21-Day (00273) - Version 4	Active
Cyclophosphamide, DOXOrubicin and CISplatin – 21 Day (00615) - Version 4	Active
cycloPHOSphamide, DOXOrubicin, vinCRISTine and prednisoLONE (CHOP)– 21 days (00841) - Version 6	Active
cycloPHOSphamide,Total Body Irradiation (TBI)–MAC–Mismatched Sibling Donor (00630) - Version 4	Active
cycloPHOSphamide,Total Body Irradiation (TBI)–MAC–Mismatched Unrelated Donor (00629) - Version 4	Active
Cyclophosphamide,Total Body Irradiation (TBI)–MAC–MUD (00631) - Version 3	Active
cycloPHOSphamide,Total Body Irradiation (TBI)–MAC–SIB (00637) - Version 4	Active
DA (50/100) (3+8) Course 2 Induction (AML-17) (00360) - Version 6	Active
DA(60/100) 3+10: Course 1 Induction (AML-17) (00359) - Version 7	Active
Dabrafenib Monotherapy (00237) - Version 4	Active
Dacarbazine (00464) - Version 3	Active
Dacarbazine (1.2g/m ²) -21 day (00511) - Version 4	Active
Dacomitinib Monotherapy (00565) - Version 2	Active
DACTINomycin (00247) - Version 3	Active
DA-R EPOCH Dose level 1 (initial dose) (00355.1) - Version 6	Active
DA-R EPOCH Dose level 2 (00355.4) - Version 2	Active
DA-R EPOCH Dose level 3 (00355.5) - Version 2	Active
DA-R EPOCH Dose level 4 (00355.6) - Version 3	Active
DA-R EPOCH Dose level 5 (00355.7) - Version 2	Active
DA-R EPOCH Dose level 6 (00355.8) - Version 2	Active
DA-R EPOCH Dose level Minus 1 (-1) (00355.3) - Version 3	Active
DA-R EPOCH Dose level Minus 2 (-2) (00355.2) - Version 1	Active
Daratumumab (IV), Bortezomib and dexAMETHasone (00560) - Version 5	Active
Daratumumab (SC 1800mg), Bortezomib (weekly) and dexAMETHasone (00695) - Version 2	Active
Daratumumab (SC 1800mg), Bortezomib and dexAMETHasone (00609) - Version 2	Active
Daratumumab (SC), Bortezomib (Once Weekly), Thalidomide and dexAMETHasone Consolidation (00756) - Version 4	Active
Daratumumab (SC), Bortezomib (Once Weekly), Thalidomide and dexAMETHasone Induction (00752) - Version 3	Active
Daratumumab (SC), Bortezomib, Thalidomide and dexAMETHasone Consolidation (00755) - Version 3	Active
Daratumumab (SC), Bortezomib, Thalidomide and dexAMETHasone Induction (00703) - Version 4	Active
Daratumumab Monotherapy (00426) - Version 6	Active

Regimen list

Regimen	Status
Daratumumab SC Monotherapy (00604) - Version 4	Active
Daratumumab SC, Lenalidomide and dexAMETHasone (00854) - Version 4	Active
Daratumumab, Bortezomib, cycloPHOSphamide and dexAMETHasone (D-VCd) (00779) - Version 5	Active
Darolutamide (00693) - Version 2	Active
Decitabine Monotherapy (00231) - Version 4	Active
Degarelix-28 day (00481) - Version 5	Active
Denosumab 120mg (00741) - Version 2	Active
Dexamethasone, riTUXimab and Cyclophosphamide (DRC) (00532) - Version 3	Active
DOCEtaxel (75), CiSPlatin (75), 5-Fluorouracil (1000),Chemoradiation and Surgery - Neoadjuvant (TCF) (00315) - Version 7	Active
DOCEtaxel /Cyclophosphamide (TC)-21 day (00250) - Version 6	Active
DOCEtaxel 75mg/m ² –Prednisolone Combination (00546) - Version 3	Active
DOCEtaxel Monotherapy 100mg/m ² - 21 day (00202) - Version 4	Active
DOCEtaxel Monotherapy 50mg/m ² – 14 day cycle (00313) - Version 7	Active
DOCEtaxel Monotherapy 75mg/m ² – 21 day cycle (00203) - Version 3	Active
DOCEtaxel(75), CiSPlatin(100) and 5-Fluorouracil(1000) Chemoradiation (Induction) TCF (00323) - Version 6	Active
DOCEtaxel(75),CiSPlatin(75), 5-Fluorouracil(750) (TCF) and Radiotherapy (00324) - Version 6	Active
DOCEtaxel, CARBOplatin and Pertuzumab/Trastuzumab (Phesgo®) (TCHP) (00789) - Version 3	Active
DOCEtaxel, CARBOplatin and Trastuzumab (subcutaneous) (TCH) - 21 days (00258.2) - Version 1	Active
DOCEtaxel, CARBOplatin and Trastuzumab IV (TCH) - 21 days (00258.1) - Version 10	Active
DOCEtaxel, CARBOplatin, Trastuzumab (SC) and Pertuzumab (TCH(SC) P) – 21 days (00731) - Version 3	Active
DOCEtaxel, CARBOplatin, Trastuzumab and Pertuzumab (TCHP) – 21 days (00722) - Version 3	Active
Dose Dense DOXOrubicin, cycloPHOSphamide (AC 60/600) 14 day followed by PACLitaxel (175) 14 day (DD AC-T) (00278) - Version 10	Active
Dose Dense DOXOrubicin, cycloPHOSphamide (AC 60/600) 14 day followed by PACLitaxel (175) 14 day and Trastuzumab Therapy (DD AC-TH) (00316) - Version 4	Active
Dose Dense DOXOrubicin, cycloPHOSphamide (AC 60/600) 14 day followed by PACLitaxel (80) 7 day (DD AC-T) (00485) - Version 9	Active
Dose Dense DOXOrubicin, cycloPHOSphamide (AC 60/600) 14 day followed by weekly PACLitaxel (80) and Trastuzumab 21 day (DD AC-TH) (00745) - Version 3	Active
Dose Dense DOXOrubicin, cycloPHOSphamide (AC 60/600) 14 day followed by weekly PACLitaxel (80) and Trastuzumab Therapy (DD AC-TH) (00433) - Version 5	Active
Dostarlimab Therapy (00819) - Version 2	Active
DOXOrubicin (25mg/m ² /day) and CiSPlatin (100mg/m ²) Therapy - 21 day cycle-ADJ (00420.2) - Version 3	Active
DOXOrubicin (25mg/m ² /day) and CiSPlatin (100mg/m ²)-21 day cycle-NADJ (00420.1) - Version 4	Active
DOXOrubicin (60) and Ifosfamide (00391) - Version 3	Active
DOXOrubicin (60mg/m ²) (00386) - Version 5	Active
DOXOrubicin (75) and Ifosfamide LA/M (00392.2) - Version 1	Active
DOXOrubicin (75) and Ifosfamide NAdj (00392.1) - Version 4	Active
DOXOrubicin 50mg/m ² /DOCEtaxel 75mg/m ² (AT 50/75)-21 day cycle (00423) - Version 3	Active
DOXOrubicin 75mg/m ² Monotherapy (00500) - Version 3	Active
DOXOrubicin, and Cyclophosphamide (AC 60/600) - 21 day (00252) - Version 3	Active
DOXOrubicin, Cyclophosphamide (AC 60/600) 21 day followed by weekly PACLitaxel (80) and weekly Trastuzumab (AC-TH) (00432) - Version 3	Active
DOXOrubicin, cycloPHOSphamide (AC 60/600) 21 day followed by weekly PACLitaxel (80) Therapy (AC-T) (00260) - Version 6	Active
Durvalumab 1500mg, Gemcitabine (1000mg/m ²) and CiSPlatin (25mg/m ²) (00897) - Version 3	Active
Durvalumab Monotherapy 10mg/Kg-14 Day (00576) - Version 5	Active

Regimen list

Regimen	Status
Durvalumab Monotherapy 1500mg – 28 Day (00655) - Version 4	Active
Eculizumab - Version 1	Active
EMA/CO Therapy (Etoposide, Methotrexate, DACTINomycin, Cyclophosphamide, vinCRISTine) (00248) - Version 3	Active
EMA/EP Therapy (Etoposide Methotrexate DACTINomycin/Etoposide CISplatin)(00264) - Version 5	Active
Encorafenib and Binimetinib (00563) - Version 3	Active
Enfortumab vedotin Monotherapy (00846) - Version 4	Active
Entrectinib- Adult (00702) - Version 2	Active
Enzalutamide Monotherapy (00233) - Version 5	Active
Epcoritamab Monotherapy (00896) - Version 1	Active
EpiRUBicin 75 + Cyclophosphamide (EC75) -21 day (00263) - Version 2	Active
epiRUBicin 90 + cycloPHOSphamide (EC90)-21 day (00262) - Version 3	Active
epiRUBicin, CISplatin and 5-Fluorouracil (ECF) - ADJ -21 day (00240.2) - Version 5	Active
epiRUBicin, CISplatin and 5-Fluorouracil (ECF) -21 day LA/M (00240.1) - Version 5	Active
epiRUBicin, CISplatin and Capecitabine (ECX) Adj (00380.2) - Version 2	Active
epiRUBicin, CISplatin and Capecitabine (ECX) LA/M (00380.3) - Version 3	Active
epiRUBicin, CISplatin and Capecitabine (ECX) NAdj (00380.1) - Version 3	Active
epiRUBicin, Oxaliplatin and 5-Fluorouracil (EOF)- 21 day (00429) - Version 5	Active
epiRUBicin, Oxaliplatin and Capecitabine (EOX) -21 day (00239) - Version 6	Active
Erdaftinib Monotherapy (00885) - Version 2	Active
eriBULin Monotherapy – 28 Day (00743) - Version 3	Active
eriBULin Monotherapy (00228) - Version 5	Active
Erlotinib Monotherapy (00219) - Version 4	Active
Escalated Dose BEACOPDAC 21 day (00837) - Version 5	Active
Escalated Dose BEACOPP 21 day (00354) - Version 4	Active
ESHAP (00838) - Version 4	Active
Etoposide and CISplatin 20mg/m ² (EP) 5 day (00301) - Version 6	Active
Etoposide and Ifosfamide - vinCRISTine, DOXOrubicin and cycloPHOSphamide (IE-VAC) – Three Weekly Intervals (00747) - Version 3	Active
Etoposide and Ifosfamide - vinCRISTine, DOXOrubicin and cycloPHOSphamide (IE-VAC) – Two Weekly Intervals (00675) - Version 4	Active
Everolimus and Exemestane (00322) - Version 4	Active
Everolimus Monotherapy (00320) - Version 4	Active
Exemestane Monotherapy Adj (00376.1) - Version 3	Active
Exemestane Monotherapy Met (00376.2) - Version 3	Active
Fedratinib Therapy (00788) - Version 2	Active
FLAG Therapy (00363) - Version 6	Active
FLAG: Ida 8mg/m ² (00362) - Version 8	Active
FLOT -14 day NAdj (00344.1) - Version 8	Active
FLOT-14 day Adj (00344.2) - Version 8	Active
FLOX (00486) - Version 5	Active
Fludarabine & cycloPHOSphamide Lymphodepletion for Axicabtagene Ciloleucel (Yescarta®) (00608) - Version 5	Active
Fludarabine & cycloPHOSphamide Lymphodepletion for Ciltacabtagene Autoleucel (Carvykti®) Multiple Myeloma (00836) - Version 1	Active
Fludarabine & cycloPHOSphamide Lymphodepletion for Tisagenlecleucel (Kymriah®) B-cell ALL (00607) - Version 6	Active
Fludarabine & cycloPHOSphamide Lymphodepletion for Tisagenlecleucel (Kymriah®) DLBCL and FL (00606) - Version 6	Active
Fludarabine and Total Body Irradiation (Flu/TBI) with post-transplant cycloPHOSphamide (PTCy) (00913) - Version 1	Active
Fludarabine, Cyclophosphamide and ritUXimab (FC IV+R) (00241) - Version 5	Active
Fludarabine, Cyclophosphamide and ritUXimab (FC Oral +R) (00410) - Version 3	Inactive
Fludarabine, Busulfan, ATG Grafalon® – RIC – MUD (00635) - Version 4	Active
Fludarabine, Busulfan, ATG Grafalon® – RIC –SIB (00636) - Version 5	Active
Fludarabine, Melphalan, Alemtuzumab-RIC-MUD (00625) - Version 4	Active

Regimen list

Regimen	Status
Fludarabine,Melphalan,Alemtuzumab-RIC-SIB (00611) - Version 4	Active
Fludarabine/ Melphalan with-post transplant cycloPHOSphamide (00868) - Version 1	Active
Fludarabine/Busulfan (FluBu2) – with post-transplant cycloPHOSphamide Therapy (PTCy) (00911) - Version 1	Active
Fludarabine/Busulfan (FluBu4) – with post-transplant cycloPHOSphamide (PTCy) (00910) - Version 1	Active
FOLFIRI 14 day (00227) - Version 9	Active
FOLFIRINOX (00329) - Version 7	Active
FOLFIRINOX Modified Adj (00515.1) - Version 5	Active
FOLFIRINOX Modified Met (00515.2) - Version 2	Active
FOLFIRINOX- Rectal Carcinoma (00691) - Version 4	Active
FOLFOX-4 14 day Adj (00210.1) - Version 9	Active
FOLFOX-4 14 day Met (00210.2) - Version 7	Active
FOLFOX-6 Modified 14 day Met (00209.2) - Version 12	Active
FOLFOX-6 Modified 14 day Adj (00209.1) - Version 13	Active
FOLFOX-6 Modified Chemoradiation-14 day (00509) - Version 7	Active
FOLFOXIRI (00555) - Version 7	Active
Fruquintinib Monotherapy (00890) - Version 3	Active
Fulvestrant (00361) - Version 3	Active
Gefitinib Monotherapy (00220) - Version 3	Active
Gemcitabine (1000mg/m ²) and RT (00521) - Version 4	Active
Gemcitabine (1000mg/m ²) and Capecitabine (650mg/m ²)-21 day (00384) - Version 3	Active
Gemcitabine (1000mg/m ²) and Capecitabine (830mg/m ²) - 28 day (00524) - Version 2	Active
Gemcitabine (1000mg/m ²) and CARBOplatin (AUC 4) - 21 day (00306) - Version 8	Active
Gemcitabine (1000mg/m ²) and CARBOplatin (AUC 5)- 21 day (00310) - Version 8	Active
Gemcitabine (1000mg/m ²) and CISplatin (25mg/m ²) - 21 day (00383) - Version 6	Active
Gemcitabine (1000mg/m ²) and CISplatin (35mg/m ²) - 21 day (00622) - Version 3	Active
Gemcitabine (1000mg/m ²) and CISplatin (70mg/m ²) - 21 day (00628) - Version 3	Active
Gemcitabine (1000mg/m ²) and CISplatin (70mg/m ²) Therapy- 28 day (00282) - Version 3	Active
Gemcitabine (1000mg/m ²) Monotherapy - 28 day Adj (00284.1) - Version 5	Active
Gemcitabine (1000mg/m ²) Monotherapy - 28 day Met (00284.2) - Version 5	Active
Gemcitabine (1000mg/m ²) Monotherapy - 56 day (00283) - Version 4	Active
Gemcitabine (1000mg/m ²), CARBOplatin (AUC 4) and Bevacizumab 15mg/kg - 21 day (00499) - Version 6	Active
Gemcitabine (1250mg/m ²) and CISplatin (75mg/m ²)- 21 day (00281) - Version 5	Active
Gemcitabine (1250mg/m ²) and CISplatin (80mg/m ²) - 21 day (00517) - Version 3	Active
Gemcitabine (1250mg/m ²) Monotherapy - 21 day (00514) - Version 3	Active
Gemcitabine (400mg/m ²) and RT (00522) - Version 4	Active
Gemcitabine (600mg/m ²) and RT-7 day (00559) - Version 4	Active
Gemcitabine (800mg/m ²) Monotherapy - 28 Day (00749) - Version 1	Active
Gemcitabine 1000mg/m ² , Vinorelbine 20mg/m ² and Pegylated Liposomal DOXOrubicin 15mg/m ² (GVD)– Transplant Naive (00853) - Version 1	Active
Gemcitabine 100mg/m ² + Radiotherapy (00759) - Version 1	Active
Gemcitabine 800mg/m ² , Vinorelbine 15mg/m ² and Pegylated Liposomal DOXOrubicin 10mg/m ² (GVD)– Post Transplant (00895) - Version 1	Active
Gemcitabine and CARBOplatin (AUC2) - 21 days (00430) - Version 4	Active
Gemcitabine and DOCEtaxel - 21 day (00501) - Version 4	Active
Gemtuzumab ozogamicin, DAUNOrubicin and cytarabine (AML induction) (00612) - Version 2	Active
Gilteritinib (00684) - Version 1	Active
Goserelin 10.8mg-12 weeks (00477) - Version 5	Active
Goserelin 3.6mg-28 day (00478) - Version 4	Active
High Dose Cytarabine (00365) - Version 4	Active

Regimen list

Regimen	Status
High Dose Cytarabine Consolidation Therapy (post R-MPV) - 28 day (00666) - Version 2	Active
High Dose Ifosfamide- 21 day (00680) - Version 2	Active
High Dose Melphalan Conditioning for Autologous Stem Cell Transplant (00454) - Version 3	Active
High Dose Methotrexate (3000mg/m ²) Therapy – 24 hour infusion (CNS prophylaxis) (00665) - Version 1	Active
High Dose Methotrexate (3000mg/m ²) Therapy 3 hour infusion (CNS prophylaxis) (00439) - Version 1	Active
High dose Methotrexate, high dose Cytarabine, riTUXimab and Thiotepa (MATRix) (00508) - Version 2	Active
Ibrutinib Therapy CLL / Waldenström's macroglobulinaemia (00296) - Version 4	Active
Ibrutinib Therapy Mantle Cell Lymphoma (00297) - Version 4	Active
ICE (Ifosfamide, CARBOplatin and Etoposide) (00842) - Version 6	Active
Idelalisib and riTUXimab (00389) - Version 3	Active
Idelalisib Monotherapy (00291) - Version 2	Active
Ifosfamide Etoposide (IE) (00596) - Version 1	Active
Ifosfamide, vinCRISTine, DOXOrubicin, DACTINomycin (IVADo) (00754) - Version 2	Active
Imatinib - GIST Adj (00335.1) - Version 4	Active
Imatinib - GIST Met (00335.2) - Version 3	Active
Inotuzumab ozogamicin Monotherapy (00537) - Version 3	Active
Intermediate Dose Cytarabine (00364) - Version 7	Active
Intrathecal Cytarabine 50mg (00870) - Version 1	Active
Intrathecal Cytarabine 70mg (00871) - Version 1	Active
Intrathecal Methotrexate for CNS prophylaxis in GTN (00249) - Version 3	Active
Intrathecal Methotrexate for haematological malignancies (00869) - Version 1	Active
Intrathecal therapy - Version 1	Active
Intravenous immunoglobulin (IVIg) - Version 1	Active
Intravenous Vinorelbine Monotherapy - 21 day (00232) - Version 4	Active
Ipilimumab Monotherapy (00105) - Version 6	Active
Irinotecan 150mg/m ² Monotherapy - 28 day (00654) - Version 2	Active
Irinotecan and Temozolomide- 21 days (00504) - Version 1	Active
Irinotecan Monotherapy - 21 days (00213) - Version 5	Active
Ivosidenib (00901) - Version 1	Active
Ixazomib, Lenalidomide and Dexamethasone- 28 day (00516) - Version 3	Active
Lapatinib and Capecitabine (00217) - Version 4	Active
Larotrectinib Monotherapy- Adult (00758) - Version 4	Active
LEAM Autologous Transplant Conditioning (00468) - Version 4	Active
Lenalidomide 25mg and dexAMETHasone- 28 day (00218) - Version 3	Active
Lenalidomide Maintenance Therapy (RVD-Lite) (00782) - Version 3	Active
Lenvatinib (Lenvima®) - DTC (00295) - Version 5	Active
Lenvatinib (Lenvima®) – HCC ≥ 60 kg (00644.2) - Version 2	Active
Lenvatinib (Lenvima®)- HCC- patients < 60kg (00644.1) - Version 2	Active
Letrozole Monotherapy Adj (00371.1) - Version 5	Active
Letrozole Monotherapy Met (00371.2) - Version 5	Active
Letrozole Monotherapy NAdj (00371.3) - Version 3	Active
Leuprorelin 11.25mg-12 weeks (00492) - Version 5	Active
Leuprorelin 22.5mg-12 weeks (00479) - Version 5	Active
Leuprorelin 3.75mg-28 days (00494) - Version 4	Active
Leuprorelin 30mg-24 weeks (00493) - Version 3	Active
Leuprorelin 45mg-24 week (00491) - Version 5	Active
Leuprorelin 7.5mg-28 day (00490) - Version 4	Active
Lomustine 130mg/m ² Therapy (00805) - Version 2	Active
Lomustine and Bevacizumab 5mg/kg (00742) - Version 4	Active
Lomustine and Bevacizumab 7.5mg/kg (00804) - Version 3	Active
Lorlatinib (00570) - Version 2	Active
Methotrexate 40mg/m ² Monotherapy -28 Day (00893) - Version 1	Active
Methotrexate 8 day Charing Cross Regimen (00246) - Version 3	Active

Regimen list

Regimen	Status
Methotrexate,vinBLASTine, DOXOrubicin, CISplatin (MVAC) -14 Days (00333) - Version 5	Active
Methotrexate,vinBLASTine, DOXOrubicin, CISplatin (MVAC) -28 Days Adj (00338.2) - Version 4	Active
Methotrexate,vinBLASTine, DOXOrubicin, CISplatin (MVAC) -28 Days Met (00338.3) - Version 4	Active
Methotrexate,vinBLASTine, DOXOrubicin, CISplatin (MVAC) -28 Days NAdj (00338.1) - Version 4	Active
Midostaurin and Intermediate Dose Cytarabine Consolidation Therapy (00683) - Version 4	Active
Midostaurin Maintenance (00661) - Version 3	Active
Midostaurin, DAUNOrubicin and Cytarabine Induction (00682) - Version 2	Active
Mifamurtide (00100) - Version 3	Active
mitoMYcin and Capecitabine Chemoradiation (00727) - Version 6	Active
Modified CyBorD/ Bortezomib, cycloPHOSphamide and dexAMETHasone – Weekly (00299) - Version 5	Active
Mogamulizumab Therapy (00761) - Version 3	Active
Momelotinib Therapy (00867) - Version 1	Active
nab-PACLitaxel and Gemcitabine - 28 day (00256) - Version 7	Active
nab-PACLitaxel Monotherapy– 21 day (00230) - Version 5	Active
nab-PACLitaxel Weekly Monotherapy–28 day (00736) - Version 4	Active
Neratinib (00720) - Version 2	Active
Nintedanib (00372) - Version 2	Active
Niraparib 200mg (Capsules) Monotherapy (00571.2) - Version 2	Active
Niraparib 200mg (Tablets) Monotherapy (00862.2) - Version 2	Active
Niraparib 300mg (Capsules) Monotherapy (00571.1) - Version 5	Active
Niraparib 300mg (Tablets) Monotherapy (00862.1) - Version 2	Active
Niraparib and Abiraterone acetate (Akeega®) and prednisoLONE (00848) - Version 2	Active
Nivolumab 1mg/kg Ipilimumab 3mg/kg (00431) - Version 5	Active
Nivolumab 240mg and Ipilimumab 1mg/kg (00900) - Version 2	Active
Nivolumab 240mg, CISplatin 80mg/m ² and 5-Fluorouracil (4 day) (00816.2) - Version 4	Active
Nivolumab 240mg, CISplatin 80mg/m ² and 5-Fluorouracil (5 day) (00816.1) - Version 4	Active
Nivolumab 360mg and Ipilimumab 1mg/kg (00792) - Version 2	Active
Nivolumab 360mg, CARBOplatin (AUC6) and PACLitaxel 200mg/m ² (00849.1) - Version 1	Active
Nivolumab 360mg, Gemcitabine (1000mg/m ²) and CARBOplatin (AUC5) (00849.2) - Version 1	Active
Nivolumab 360mg, Gemcitabine 1250mg/m ² and CISplatin 75mg/m ² (00849.3) - Version 1	Active
Nivolumab 360mg, PEMEtrexed and CARBOplatin (00849.4) - Version 1	Active
Nivolumab 360mg, PEMEtrexed and CISplatin (00849.5) - Version 1	Active
Nivolumab 3mg/kg with Ipilimumab 1mg/kg (00551) - Version 5	Active
Nivolumab 480mg, CISplatin 80mg/m ² and 5-Fluorouracil (4 day) (00832.2) - Version 4	Active
Nivolumab 480mg, CISplatin 80mg/m ² and 5-Fluorouracil (5 day) (00832.1) - Version 4	Active
Nivolumab and FOLFOX-6 Modified (00844) - Version 4	Active
Nivolumab and XELOX (00843) - Version 2	Active
Nivolumab Monotherapy 240mg - 14 days (00483.1) - Version 11	Active
Nivolumab Monotherapy 240mg - 14 days Adj (26 cycles)(00483.2) - Version 8	Active
Nivolumab Monotherapy 480mg-28 days (00484.1) - Version 11	Active
Nivolumab Monotherapy 480mg-28 days Adj (13 cycles) (00484.2) - Version 9	Active
Nivolumab, ipilimumab, CARBOplatin and PACLitaxel (00712) - Version 5	Active
Nivolumab, ipilimumab, PEMEtrexed and CARBOplatin (AUC 5) (00713.1) - Version 6	Active
Nivolumab, ipilimumab, PEMEtrexed and CARBOplatin (AUC 6) (00713.2) - Version 6	Active
Nivolumab, ipilimumab, PEMEtrexed and CISplatin (00714) - Version 4	Active
Nordic Therapy (00393) - Version 4	Active

Regimen list

Regimen	Status
Obinutuzumab and Bendamustine-28 day cycle (00424) - Version 6	Active
Obinutuzumab and Chlorambucil (00286) - Version 4	Active
Obinutuzumab cycloPHOSphamide vinCRiStine and prednisoLONE (O-CVP)-21 days (00550) - Version 7	Active
Obinutuzumab Maintenance Therapy-56 day (00425) - Version 6	Active
Obinutuzumab, cycloPHOSphamide, DOXOrubicin, vinCRiStine and prednisoLONE (O-CHOP)-21 day (00549) - Version 6	Active
Olaparib (Capsule) Monotherapy (00341) - Version 3	Active
Olaparib (Tablet) and Bevacizumab (00746) - Version 2	Active
Olaparib (Tablet) Monotherapy (00588) - Version 4	Active
Oral Etoposide (00388) - Version 4	Active
Oral Vinorelbine Monotherapy-7 days (00259) - Version 5	Active
Osimertinib Monotherapy Adj (00353.2) - Version 1	Active
Osimertinib Monotherapy Met (00353.1) - Version 3	Active
PACLitaxel (80) and Trastuzumab-7 day (12 weeks) (00512) - Version 5	Active
PACLitaxel (Day 1, 8 and 15) and Cetuximab (Day 1 and 15) – 28 day (00696) - Version 2	Active
PACLitaxel 80 IV (7 day) and Trastuzumab IV (21 day) (00815.1) - Version 3	Active
PACLitaxel 80 IV (7 day) and Trastuzumab SC (21 day) (00815.2) - Version 2	Active
PACLitaxel 80mg/m ² Day 1, 8 and 15 Monotherapy-28 Day (00621) - Version 5	Active
PACLitaxel Monotherapy 80mg/m ² Day 1, 8, 15 and 22 – 28 Day (00226) - Version 11	Active
PACLitaxel, Ifosfamide, and CISplatin (TIP) (00602) - Version 2	Active
PACLitaxel/CISplatin alternating with PACLitaxel/Etoposide (TP/TE) (00266) - Version 3	Active
Palbociclib-28 day (00414) - Version 4	Active
Panitumumab 6mg/kg (00225) - Version 5	Active
Panitumumab 6mg/kg and FOLFIRI -14 day (00448) - Version 6	Active
Panitumumab 6mg/kg and Modified FOLFOX-6 – 14 day (00447) - Version 7	Active
PAZOPanib (00445) - Version 1	Active
Pegylated Liposomal DOXOrubicin 20 mg/m ² - 21 days (00462) - Version 5	Active
Pegylated Liposomal DOXOrubicin 50mg/m ² -28 days (00205) - Version 7	Active
Pembrolizumab 200mg (NAdj and Adj), CARBOplatin AUC 5 and weekly PACLitaxel 80mg/m ² followed by DOXOrubicin and cycloPHOSphamide (AC 60/600) (00857.1) - Version 2	Active
Pembrolizumab 200mg (NAdj and Adj), weekly CARBOplatin AUC 1.5 and PACLitaxel 80mg/m ² followed by DOXOrubicin and cycloPHOSphamide (AC 60/600) (00858.1) - Version 2	Active
Pembrolizumab 200mg (NAdj) and 400mg (Adj), CARBOplatin AUC 5 and weekly PACLitaxel 80mg/m ² followed by DOXOrubicin and cycloPHOSphamide (AC 60/600) (00857.2) - Version 1	Active
Pembrolizumab 200mg (NAdj) and 400mg (Adj), weekly CARBOplatin AUC 1.5 and PACLitaxel 80mg/m ² followed by DOXOrubicin and cycloPHOSphamide (AC 60/600) (00858.2) - Version 1	Active
Pembrolizumab 200mg and Axitinib (00583) - Version 3	Active
Pembrolizumab 200mg Monotherapy (00455.1) - Version 15	Active
Pembrolizumab 200mg Monotherapy Adj (18 cycles) (00455.2) - Version 11	Active
Pembrolizumab 200mg, CISplatin 80mg/m ² and 5-Fluorouracil (4 day) (00739.2) - Version 5	Active
Pembrolizumab 200mg, CISplatin 80mg/m ² and 5-Fluorouracil (5 day) (00739.1) - Version 5	Active
Pembrolizumab 400mg Monotherapy (00558.1) - Version 15	Active
Pembrolizumab 400mg Monotherapy Adj (9 cycles) (00558.2) - Version 11	Active
Pembrolizumab 400mg, CARBOplatin AUC 5 and weekly PACLitaxel 80mg/m ² followed by Dose Dense DOXOrubicin and cycloPHOSphamide (AC 60/600) (00860) - Version 3	Active
Pembrolizumab 400mg, Weekly CARBOplatin AUC 1.5 and PACLitaxel 80mg/m ² followed by Dose Dense DOXOrubicin and cycloPHOSphamide (AC 60/600) (00861) - Version 3	Active

Regimen list

Regimen	Status
Pembrolizumab and FOLFOX-6 Modified (00839) - Version 4	Active
Pembrolizumab, CARBOplatin (AUC 5) and 5-Fluorouracil Therapy (00705) - Version 6	Active
Pembrolizumab, CISplatin and 5-Fluorouracil (00706) - Version 4	Active
Pembrolizumab, PACLitaxel 175mg/m ² and CARBOplatin AUC 5 (00817) - Version 2	Active
Pembrolizumab, PACLitaxel 175mg/m ² , CARBOplatin AUC 5 and Bevacizumab (00811) - Version 2	Active
Pembrolizumab, PACLitaxel 200mg/m ² and CARBOplatin (AUC 6) (00579) - Version 7	Active
Pembrolizumab, PEMEtrexed and CARBOplatin (AUC 5) (00568) - Version 5	Active
Pembrolizumab, PEMEtrexed and CISplatin (00569) - Version 3	Active
PEMEtrexed and CARBOplatin (00318) - Version 9	Active
PEMEtrexed and CISplatin (00317) - Version 6	Active
PEMEtrexed Monotherapy (00222) - Version 5	Active
Pemigatinib Therapy (00889) - Version 2	Active
Pentamidine isetionate prophylactic therapy - Version 2	Active
Pertuzumab and Trastuzumab (Continuation) (00726) - Version 5	Active
Pertuzumab and Trastuzumab (Phesgo®) and DOCEtaxel - 21 day cycle (00796) - Version 5	Active
Pertuzumab and Trastuzumab (Phesgo®) Maintenance Therapy (00785) - Version 3	Active
Pertuzumab and Trastuzumab and Chemotherapy - 21 day cycle Adj (00350.2) - Version 5	Active
Pertuzumab and Trastuzumab and Chemotherapy - 21 day cycle NAdj (00350.1) - Version 5	Active
Pertuzumab and Trastuzumab and DOCEtaxel Therapy - 21 day (00204) - Version 6	Active
Pertuzumab Trastuzumab (Phesgo®) and Vinorelbine (00798.1) - Version 3	Active
Pertuzumab Trastuzumab (Phesgo®) and Vinorelbine (Oral Vinorelbine) (00798.2) - Version 2	Active
Pertuzumab Trastuzumab and Vinorelbine (00526.1) - Version 6	Active
Pertuzumab Trastuzumab and Vinorelbine (Oral Vinorelbine) (00526.2) - Version 2	Active
Pertuzumab Trastuzumab and Weekly PACLitaxel - 21 day cycle (00507) - Version 6	Active
Pertuzumab, Trastuzumab, PACLitaxel and CARBOplatin (TRAIN-2) (00775) - Version 3	Active
Pertuzumab/Trastuzumab (Phesgo®) and Weekly PACLitaxel - 21 day (00797) - Version 4	Active
Pertuzumab/Trastuzumab (Phesgo®), PACLitaxel and CARBOplatin (TRAIN-2) (00790) - Version 3	Active
Pixantrone Therapy (00255) - Version 4	Active
Plerixafor and G-CSF (00536) - Version 3	Active
Polatuzumab Vedotin, Bendamustine and riTUXimab (00685) - Version 5	Active
Polatuzumab Vedotin, riTUXimab, cycloPHOSphamide, DOXOrubicin and prednisoLONE (00833) - Version 5	Active
Pomalidomide and Dexamethasone (00245) - Version 6	Active
Pomalidomide, Bortezomib and dexAMETHasone (PVD) (00601.1) - Version 4	Active
Pomalidomide, Bortezomib and dexAMETHasone (PVD)(for cycles 1-8 weekly administration Bortezomib) (00601.2) - Version 2	Active
PONATinib (00302) - Version 2	Active
Procarbazine Lomustine and vinCRISTine (PCV) (00379) - Version 6	Active
Procarbazine, Lomustine and vinCRISTine (PCV) Therapy – 56 days (00658) - Version 3	Active
QUASAR (Modified) 5-Fluorouracil (370mg/m ²) and Folinic Acid (50mg) Weekly Adj (00428.1) - Version 7	Active
QUASAR (Modified) 5-Fluorouracil (370mg/m ²) and Folinic Acid (50mg) Weekly Met (00428.2) - Version 6	Active
Quizartinib and Intermediate Dose Cytarabine Consolidation Therapy (00887) - Version 1	Active
Quizartinib Maintenance (00888) - Version 1	Active

Regimen list

Regimen	Status
Quizartinib, DAUNOrubicin and Cytarabine Induction (00886) - Version 1	Active
Quizartinib, IDArubicin and Cytarabine Induction (00891) - Version 1	Active
R- miniCHOP - 21 days (00436) - Version 6	Active
R-CEOP – 21 days (00510) - Version 4	Active
R-CODOX-M (Patients >65 years) (00403) - Version 3	Active
R-CODOX-M (Patients ≤65yrs) (00398) - Version 3	Active
R-DHAP (00395) - Version 3	Active
Regorafenib Monotherapy (00244) - Version 5	Active
Relugolix (00830) - Version 3	Active
R-ESHAP (00394) - Version 6	Active
R-Gemcitabine (1000mg/m ²) Oxaliplatin - 14 day (00506) - Version 3	Active
Ribociclib (Adjuvant) - 28 day (00892) - Version 2	Active
Ribociclib (Metastatic) - 28 day (00525) - Version 4	Active
R-ICE (riTUXimab), Ifosfamide, CARBOplatin and Etoposide - Outpatient (00751) - Version 4	Active
R-ICE (riTUXimab), Ifosfamide, CARBOplatin and Etoposide) (00397) - Version 8	Active
riTUXimab (S/C 1400mg) Maintenance - 56 day (00600) - Version 4	Active
riTUXimab (S/C 1400mg) Maintenance - 84 day (00599) - Version 4	Active
RiTUXimab 375 mg/m ² - 7 day (00541) - Version 3	Active
riTUXimab 375 mg/m ² Combination Therapy-21 day (00542) - Version 4	Active
RiTUXimab 375 mg/m ² Maintenance Therapy- 56 day (00543) - Version 5	Active
RiTUXimab 375mg/m ² - Follicular Lymphoma (every 2 months) - Version 2	Inactive
RiTUXimab 375mg/m ² - Follicular Lymphoma (every 3 months) - Version 2	Inactive
RiTUXimab 375mg/m ² - Follicular Lymphoma (once weekly for four weeks) - Version 2	Inactive
RiTUXimab 375mg/m ² Maintenance-84 day (00540) - Version 5	Active
riTUXimab and Bendamustine (00345) - Version 6	Active
riTUXimab S/C, cycloPHOSphamide, DOXOrubicin, vinCRISline and prednisoLONE (R-CHOP) – 21 Days (00667) - Version 4	Active
riTUXimab* Gemcitabine, Dexamethasone and ClSplatin ((R*)-GDP) (00441) - Version 3	Active
riTUXimab*, dexAMETHasone, Cytarabine and Oxaliplatin ((*R)-DHAOx) (00834) - Version 1	Active
riTUXimab, Methotrexate, Procarbazine and vinCRISline (R-MPV) – 14 Days Induction (00664) - Version 4	Active
riTUXimab-HyperCVAD (MCL) – Part A (00466) - Version 2	Active
riTUXimab-Methotrexate and Cytarabine Therapy (MCL) - Hyper CVAD Part B (00467) - Version 1	Active
R-IVAC (Patients >65 years) (00404) - Version 3	Active
R-IVAC (patients ≤ 65 years) (00399) - Version 3	Active
Roswell Park Modified (5-Fluorouracil 500mg/m ² and Folinic Acid 50mg weekly x 6) Regimen Adj (00427.2) - Version 7	Active
Roswell Park Modified (5-Fluorouracil 500mg/m ² and Folinic Acid 50mg weekly x 6) Regimen Met (00427.1) - Version 7	Active
Rucaparib (Tablets) Monotherapy (00904) - Version 1	Active
Ruxolitinib Monotherapy (00229) - Version 3	Active
Sacituzumab Govitecan (00794) - Version 3	Active
Serplulimab, CARBOplatin AUC5 and Etoposide (Day 1 IV, Day 2 & 3 oral) – 21 Day (00908.2) - Version 1	Active
Serplulimab, CARBOplatin AUC5 and Etoposide 100mg/m ² – 21 Day (00908.1) - Version 1	Active
Siltuximab Monotherapy (00277) - Version 4	Active
SMILE (NK or T-cell lymphoma) (00407) - Version 2	Active
SORafenib (00294) - Version 3	Active
SUNitinib 37.5mg - 28 Days (00327) - Version 2	Active
SUNitinib 50mg - 42 days (00325) - Version 3	Active
SUNitinib 50mg (21 days) (00719) - Version 2	Active
Tafasitamab and Lenalidomide (00774) - Version 2	Active
Talazoparib (00605) - Version 3	Active
Tamoxifen Monotherapy Adj (00253.1) - Version 3	Active

Regimen list

Regimen	Status
Tamoxifen Monotherapy Met (00253.2) - Version 3	Active
Teclistamab Monotherapy (00865) - Version 3	Active
Temozolomide Recurrent Therapy (00342) - Version 4	Active
Temozolomide with Radiotherapy (RT) and Adjuvant Therapy - Patients greater than 65 years (00461) - Version 4	Active
Temozolomide with Radiotherapy (RT) and Adjuvant Therapy (00334) - Version 4	Active
Temsirolimus Monotherapy (00326) - Version 5	Active
Tepotinib Therapy (00823) - Version 1	Active
TESTING Regimen - Version 1	Active
Tivozanib Therapy (00564) - Version 2	Active
Topotecan Monotherapy – 5 day (00311) - Version 5	Active
Topotecan Monotherapy – Weekly (00312) - Version 5	Active
Topotecan Oral Monotherapy (00587) - Version 3	Active
Trabectedin and Pegylated Liposomal DOXOrubicin (PLD) (00375) - Version 4	Active
Trabectedin Monotherapy (00374) - Version 3	Active
Trametinib and Dabrafenib Adj (00415.2) - Version 2	Active
Trametinib and Dabrafenib Met (00415.1) - Version 3	Active
Transcription only. See original prescription. - Version 1	Active
Trastuzumab (IV) Monotherapy - 21 days Adj (00200.1) - Version 7	Active
Trastuzumab (IV) Monotherapy - 7 days (00201) - Version 6	Active
Trastuzumab (IV) Monotherapy- 21 days Met (00200.2) - Version 6	Active
Trastuzumab 5-Fluorouracil and CISplatin - 21 days (00502) - Version 6	Active
Trastuzumab and FOLFOX-6 Modified - 14 day (00704) - Version 5	Active
Trastuzumab deruxtecan (Enhertu®) (00776) - Version 4	Active
Trastuzumab Emtansine (Kadcyla®) - 21 days (00206) - Version 4	Active
Trastuzumab Emtansine (Kadcyla®) Early Breast Cancer Therapy- 21 days (00659) - Version 3	Active
Trastuzumab Subcutaneous 21 days - Metastatic Breast Cancer (00272) - Version 6	Active
Trastuzumab Subcutaneous 21 days - Early Breast Cancer (00285) - Version 7	Active
Tretinoin (ATRA) with Arsenic Trioxide (ATO) Consolidation (00357) - Version 3	Active
Tretinoin (ATRA) with Arsenic Trioxide (ATO) Induction (00356) - Version 3	Active
Tretinoin (ATRA/IDArubicin (PETHEMA AIDA) Induction: High Risk (00366) - Version 2	Active
Trifluridine and Tipiracil (Lonsurf ®) (00382) - Version 1	Active
Triple Intrathecal Therapy (00873) - Version 1	Active
Triptorelin 11.25mg-12 weeks (00480) - Version 4	Active
Triptorelin 22.5mg-24 weeks (00488) - Version 4	Active
Triptorelin 3mg-28 day (00489) - Version 3	Active
Two Day Etoposide CISplatin (EP) (00267) - Version 3	Active
UKALL2011 – Regimen Maintenance B1 - Version 1	Active
UKALL2019 – Regimen B Delayed Intensification - Version 1	Active
UKALL2019 – Regimen B Induction - Version 1	Active
UKALL2019 – Regimen B Maintenance - Version 1	Active
UKALL2019 – Regimen B Standard BFM Consolidation - Version 2	Active
Vandetanib Therapy (00242) - Version 3	Active
Vemurafenib Monotherapy (00102) - Version 5	Active
Venetoclax and azaCITIDine 100mg/m ² Days 1-5 (00852.2) - Version 4	Active
Venetoclax and azaCITIDine 75mg/m ² Days 1-5 and 8-9 (00852.1) - Version 4	Active
Venetoclax and Obinutuzumab (00715) - Version 4	Active
Venetoclax and riTUXimab (00575) - Version 3	Active
Venetoclax Monotherapy (00400) - Version 4	Active
VinBLAStine and Methotrexate (00554) - Version 2	Active
vinCRIStine, Irinotecan and Temozolomide (VIT) (00757) - Version 2	Active
Vinorelbine 30 (Day 1,8,15) and CISplatin 80 (Day1) Therapy- 21 day (00339) - Version 4	Active

Regimen list

Regimen	Status
Vinorelbine and CISplatin Therapy - 28 day (00343) - Version 4	Active
Vismodegib Monotherapy (00236) - Version 5	Active
Vyxeos liposomal® (DAUNOrubicin and cytarabine) Consolidation (00618) - Version 3	Active
Vyxeos liposomal® (DAUNOrubicin and cytarabine) Induction (00613) - Version 2	Active
Weekly CARBOplatin (AUC2) PACLitaxel 50mg/m ² with Radiotherapy (00309) - Version 9	Active
Zanubrutinib (00708) - Version 2	Active
Zoledronic Acid -28 days (00723) - Version 2	Active
Zoledronic Acid- 3 monthly (00724) - Version 3	Active
Zoledronic Acid- 6 monthly (00725) - Version 3	Active
Zoledronic Acid Monotherapy (00545) - Version 4	Active